Trial · NCT01200602
Megestrol Acetate in Treating Weight Loss or Anorexia in Young Patients With Malignancies Who Are Undergoing Radiation Therapy and/or Chemotherapy
NCT01200602, Phase 2, Terminated, Mayo Clinic; results first posted 2013-05-24
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Megestrol Acetate in Treating Weight Loss or Anorexia in Young Patients With Malignancies Who Are Undergoing Radiation Therapy and/or Chemotherapy. Trials, record NCT01200602. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01200602
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Megestrol Acetate in Treating Weight Loss or Anorexia in Young Patients With Malignancies Who Are Undergoing Radiation Therapy and/or Chemotherapy
- NCT number
- NCT01200602
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 1 participants, actual
- Lead sponsor
- Mayo Clinic
- Conditions
- Anorexia, Weight Changes
- Interventions
- megestrol acetate, clinical observation
- First posted
- 2010-09-13
- Last updated
- 2015-11-25
- Results first posted
- 2013-05-24
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of Patients Who Maintain Weight or Experience Weight Gain | 4 weeks | A patient will be defined as "success" if he/she maintains or gains weight at the end if Initial Treatment compared with baseline of study entry. |
| Secondary | BMI Trends | 4 weeks | |
| Secondary | Caloric Intake | 4 weeks | |
| Secondary | Weight Maintenance Over Time | 4 weeks | |
| Secondary | Toxicity Profile | 4 weeks | Number of patients with grade 3+ non-hematologic adverse events using Common Toxicity Criteria for Adverse Effects (CTCAE) v.4.0 |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Proportion of Patients Who Maintain Weight or Experience Weight Gain | 4 weeks | Since only one patient was accrued, patient confidentiality prevents the reporting of this patient. | ||
| SECONDARY | BMI Trends | 4 weeks | Since only one patient was accrued, patient confidentiality prevents the reporting of this patient. | ||
| SECONDARY | Caloric Intake | 4 weeks | Since only one patient was accrued, patient confidentiality prevents the reporting of this patient. | ||
| SECONDARY | Weight Maintenance Over Time | 4 weeks | Since only one patient was accrued, patient confidentiality prevents the reporting of this patient. | ||
| SECONDARY | Toxicity Profile | 4 weeks | Since only one patient was accrued, patient confidentiality prevents the reporting of this patient. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Arm A | 0 | |
| Overall Study | STARTED | Arm B | 0 | |
| Overall Study | COMPLETED | Arm A | 0 | |
| Overall Study | COMPLETED | Arm B | 0 | |
| Overall Study | NOT COMPLETED | Arm A | 0 | |
| Overall Study | NOT COMPLETED | Arm B | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Arm A | ||
| Total, all-cause mortality | Arm B | ||
| Total, other adverse events | Arm A | 0 | 0 |
| Total, other adverse events | Arm B | 0 | 0 |
| Total, serious adverse events | Arm A | 0 | 0 |
| Total, serious adverse events | Arm B | 0 | 0 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01200602
GET https://conductscience.org/api/trials/v1/NCT01200602/registered